EHA 2019 | Key EHA data, and what to watch for at ASH
Ulrich Jäger, MD , Medical University of Vienna, Vienna, Austria, discusses the key data from EHA, and what he will be following in the lead-up to ASH at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Transcript (edited for clarity)
I think, once again, it’s the cellular therapies, so where we’ll be going in the future. There will be updates from the major clinical trials in lymphoma and acute leukemia. We are seeing data on other indications, like myeloid indications...
I think, once again, it’s the cellular therapies, so where we’ll be going in the future. There will be updates from the major clinical trials in lymphoma and acute leukemia. We are seeing data on other indications, like myeloid indications. Translational research is extremely helpful in this respect, and then, of course, in all other fields, in the malignant fields, we will see treatment studies with inhibitors, combinations of inhibitors, and I think it’s almost impossible to pick out one or the other trial.
That’s also something that I noticed, that even during the last years at EHA, we are seeing more good science, because, in recent years, education was the best asset, but now we are seeing all these trials, and it’s incredible. It’s hard to pick one.
I would also think that a field where we see a lot of development is the field of benign hematology, small indications, for instance, autoimmune hemolytic anemia, so PNH, where we get decisive new treatments that will change our treatment [inaudible].
Read more...
